Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company focused on developing precision medicines for renal, metabolic and cardiovascular diseases, has announced its participation in two upcoming investor conferences in July 2025.
Management will participate in fireside chats at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14 at 2:30 p.m. ET and the BTIG Virtual Biotech Conference on July 30 at 9:20 a.m. ET. Webcasts will be available on the company's website and archived for 60 days.
Maze Therapeutics (NASDAQ:MAZE), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie di precisione per malattie renali, metaboliche e cardiovascolari, ha annunciato la sua partecipazione a due conferenze per investitori previste per luglio 2025.
Il management prenderà parte a colloqui informali durante il 4° Annual Kidney Virtual Conference di H.C. Wainwright il 14 luglio alle 14:30 ET e al BTIG Virtual Biotech Conference il 30 luglio alle 9:20 ET. Le trasmissioni in streaming saranno disponibili sul sito web dell'azienda e archiviate per 60 giorni.
Maze Therapeutics (NASDAQ:MAZE), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos de precisión para enfermedades renales, metabólicas y cardiovasculares, ha anunciado su participación en dos próximas conferencias para inversores en julio de 2025.
La dirección participará en charlas informales en la 4ª Conferencia Virtual Anual de Riñón de H.C. Wainwright el 14 de julio a las 2:30 p.m. ET y en la Conferencia Virtual de Biotecnología de BTIG el 30 de julio a las 9:20 a.m. ET. Las transmisiones en vivo estarán disponibles en la página web de la compañía y se archivarán durante 60 días.
Maze Therapeutics (NASDAQ:MAZE)는 신장, 대사 및 심혈관 질환을 위한 정밀 의약품 개발에 주력하는 임상 단계의 바이오제약 회사로, 2025년 7월에 열리는 두 차례의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다.
경영진은 7월 14일 오후 2시 30분(동부시간)에 열리는 H.C. Wainwright 제4회 연례 신장 가상 컨퍼런스와 7월 30일 오전 9시 20분(동부시간)에 열리는 BTIG 가상 바이오텍 컨퍼런스에서 파이어사이드 채팅에 참여할 예정입니다. 웹캐스트는 회사 웹사이트에서 제공되며 60일간 아카이브됩니다.
Maze Therapeutics (NASDAQ:MAZE), une société biopharmaceutique en phase clinique spécialisée dans le développement de médicaments de précision pour les maladies rénales, métaboliques et cardiovasculaires, a annoncé sa participation à deux conférences pour investisseurs prévues en juillet 2025.
La direction participera à des discussions informelles lors de la 4e conférence virtuelle annuelle sur les reins de H.C. Wainwright le 14 juillet à 14h30 ET et à la conférence virtuelle biotechnologique BTIG le 30 juillet à 9h20 ET. Les webdiffusions seront disponibles sur le site de la société et archivées pendant 60 jours.
Maze Therapeutics (NASDAQ:MAZE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung präziser Medikamente für Nieren-, Stoffwechsel- und Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Juli 2025 angekündigt.
Das Management wird an Fireside-Chats auf der 4. jährlichen virtuellen Nierenkonferenz von H.C. Wainwright am 14. Juli um 14:30 Uhr ET und der BTIG Virtuellen Biotech-Konferenz am 30. Juli um 9:20 Uhr ET teilnehmen. Webcasts werden auf der Website des Unternehmens verfügbar sein und 60 Tage lang archiviert.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that company management will participate in fireside chats during two upcoming investor conferences in July:
- H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:30 p.m. ET
- BTIG Virtual Biotech Conference on Wednesday, July 30, 2025, at 9:20 a.m. ET
Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Amanda Lazaro, 1AB
amanda@1abmedia.com
FAQ
When is Maze Therapeutics (MAZE) presenting at the H.C. Wainwright Kidney Conference?
When is Maze Therapeutics (MAZE) presenting at the BTIG Biotech Conference?
Where can I watch Maze Therapeutics (MAZE) conference presentations?
What type of medicines does Maze Therapeutics (MAZE) develop?
